Targets › DGK
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Oct 2027.
Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on DGUOK and TK2. (UniProt, Q16854)
Open in Phaseline: the race on DGK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CellSight Technologies | [18F]F-AraG Radiolabeled substrate for deoxyguanosine kinase (dGK) and deoxycytidine kinase (dCK), bot | DGK, DCK | Phase 2 | Covid19 | Oct 2027 |
Covid19 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.